Evercore ISI Group Rates Travere Therapeutics (TVTX) buy

Evercore ISI analyst Liisa Bayko reaffirmed a buy rating on Travere Therapeutics, Inc. (NasdaqGM: TVTX) on June 18, 2026. The firm set a price target of $60.00 for the biopharmaceutical company, which specializes in treatments for rare kidney and metabolic diseases. This rating comes as the company continues to advance its clinical pipeline and expand its commercial footprint.

Travere Therapeutics Valuation and Price Target

The $60.00 price target from Evercore ISI suggests the firm sees room for growth from the current price level. With the stock trading at $55.95 on Thursday, the target sits about $4.00 higher than its current market value. This is a relatively conservative target compared to some other Wall Street firms, yet it maintains the optimistic buy-side stance the firm has held previously. The gap between the current price and the $60.00 target indicates a steady, rather than aggressive, expectation for near-term appreciation.

Travere Therapeutics Stock Performance Trends

Travere's stock has shown substantial momentum over the past year. While it was trading at $55.95 on Thursday, it has stayed comfortably above its 200-day moving average of $43.89, which is often used by traders to gauge long-term health. The stock has seen a wide trading range, moving between $22.05 and $68.73 over the last 52 weeks. With a market capitalization of $5.93 billion, the company is a significant player in the mid-cap biotechnology space.

Recent Earnings and Financial Health

In its most recent financial reports, Travere Therapeutics posted revenue of $591.33 million, representing a 48.2% increase compared to the prior year. Despite this growth, the company is not yet profitable, reporting a net margin of -7.35% and earnings per share of -$0.73. Its return on equity stands at -2.36%. However, the company maintains a strong liquidity position with a current ratio of 4.04, which suggests it has enough cash and short-term assets to cover its immediate obligations. Investors are looking toward October 29, 2026, when the company is expected to release its next set of quarterly results.

Analysts Set New Price Targets

Other Wall Street firms have also updated their views on the stock recently, often with higher price targets than Evercore ISI. On September 24, 2026, Guggenheim maintained a buy rating and raised its target to $89.00 from $75.00. Wedbush reiterated an outperform rating on September 22, 2026, with a $76.00 target, while HC Wainwright & Co. also reiterated a buy rating that same day with a $67.00 target. Earlier in August, Citigroup maintained a buy rating with an $85.00 target, and TD Cowen set its target at $75.00. Currently, 14 analysts follow the stock, resulting in a consensus recommendation of strong buy and a mean price target of $74.21.

Rare Disease Focus

Travere Therapeutics focuses on delivering therapies for people living with rare kidney and metabolic conditions. Its primary products include Filspari, used for IgA Nephropathy, and Thiola for cystinuria. The company is also developing Pegtibatinase for classical homocystinuria. Because the company is still scaling its commercial products and investing heavily in clinical trials, its forward P/E ratio of 11.08 reflects future earnings expectations rather than its current loss-making status.

What's Ahead for Travere Therapeutics, Inc.

The focus for Travere investors will likely remain on the commercial rollout of Filspari and progress in its clinical-stage programs. The next major catalyst will be the earnings report on October 29, 2026. While analyst ratings provide a snapshot of professional sentiment, they represent opinions at a specific point in time and can change based on new clinical data or market shifts.